Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 7, 2011, Pages 1492-1504

  Kopecka, Joanna ^a   Campia, Ivana ^a   Brusa, Davide ^b   Doublier, Sophie ^a   Matera, Lina ^a,b   Ghigo, Dario ^a   Bosia, Amalia ^a   Riganti, Chiara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Calreticulin; Colon cancer; Dendritic cells; Doxorubicin; Drug resistance; Nitric oxide; P glycoprotein; Phagocytosis

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CALRETICULIN; CYCLIC GMP; DOXORUBICIN; GLYCOPROTEIN P; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL; ARTICLE; CELL STRAIN HT29; COLON TUMOR; CYTOSKELETON; DENDRITIC CELL; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; PHAGOCYTOSIS; PHYSIOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CALRETICULIN; COLONIC NEOPLASMS; CYCLIC GMP; CYTOSKELETON; DENDRITIC CELLS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; P-GLYCOPROTEIN; PHAGOCYTOSIS;

EID: 79959443139     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01137.x     Document Type: Article

References (26)

1. Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta. 1999; 1411: 401-14.
2. Riganti C, Doublier S, Costamagna C, et al Activation of nuclear factor-kB pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008; 74: 476-84.
3. Lind DS, Kontaridis MI, Edwards PD, et al Nitric oxide contributes to adriamycin's antitumor effect. J Surg Res. 1997; 69: 283-7.
4. Riganti C, Miraglia E, Viarisio D, et al Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res. 2005; 65: 516-25.
5. Takara K, Sakaeda T, Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des. 2006; 12: 273-86.
6. De Boo S, Kopecka J, Brusa D, et al iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer. 2009; 8: 108.
7. Chaput N, De Botton S, Obeid M, et al Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med. 2007; 85: 1069-76.
8. Apetoh L, Mignot G, Panaretakis T, et al Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med. 2008; 14: 141-51.
9. Obeid M, Testiere A, Ghiringhelli F, et al Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007; 13: 54-61.
10. Obeid M, Tesniere A, Panaretakis T, et al Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev. 2007; 220: 22-34.
11. Ghigo D, Riganti C, Gazzano E, et al Cycling of NADPH by glucose 6-phosphate dehydrogenase optimizes the spectrophotometric assay of nitric oxide synthase activity in cell lysates. Nitric Oxide. 2006; 15: 148-53.
12. Brusa D, Garetto S, Chiorino G, et al Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine. 2008; 26: 6422-32.
13. Wojciak-Stothard B, Torondel B, Zhao L, et al Modulation of Rac1 activity by ADMA/DDAH regulates pulmonary endothelial barrier function. Mol Biol Cell. 2009; 20: 33-42.
14. Chen H, Levine YC, Golan DE, et al Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem. 2008; 283: 4439-47.
15. Pratesi G, Petrangolini G, Tortoreto M, et al Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 2005; 65: 6388-93.
16. Braly P, Nicodemus CF, Chu C, et al The immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother. 2009; 32: 54-65.
17. Stoychkov JN, Schultz RM, Chirigos MA, et al Effects of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res. 1979; 39: 3014-17.
18. Ho RL, Maccubbin D, Zaleskis G, et al Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res. 1993; 5: 373-81.
19. Weigert A, Brüne B. Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide. 2008; 19: 95-102.
20. Banerjea A, Ahmed S, Hands RE, et al Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity. Mol Cancer. 2004; 3: 21-32.
21. Tufi R, Panaretakis T, Bianchi K, et al Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ. 2008; 15: 274-82.
22. Oyadomari S, Takeda K, Takiguchi M, et al Nitric oxide-induced apoptosis in pancreatic b cells is mediated by the endoplasmic reticulum stress pathway. Proc Nat Acad Sci. 2001; 98: 10845-50.
23. Panaretakis T, Joza N, Modjtahedi N, et al The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008; 15: 1499-509.
24. Molinari A, Calcabrini A, Meschini S, et al Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci. 2002; 3: 653-70.
25. Van Duyn Graham L, Sweetwyne MT, Pallero MA, et al Intracellular calreticulin regulates multiple steps in fibrillar collagen expression, trafficking, and processing into the extracellular matrix. J Biol Chem. 2010; 285: 7067-78.
26. MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotech. 2009; 27: 643-54.